Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Stride, Inc. securities during the specified Class Period, indicating potential investor claims for compensation due to misleading statements made by the company [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between October 22, 2024, and October 28, 2025, inclusive [1]. - Investors who purchased Stride securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by January 12, 2026, to represent other class members in the litigation [3]. Group 2: Allegations Against Stride, Inc. - The lawsuit claims that Stride made misleading statements regarding its products and services to educational institutions, which included inflated enrollment numbers and non-compliance with statutory requirements [5]. - Stride allegedly misrepresented its ability to help learners reach their full potential, while in reality, it was cutting staff costs excessively and losing enrollments [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Nidec Corporation (OTC: NJDCY) resulting from allegations that Nidec Corporation may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Nidec Corporation securities you may be entitled to compensation without payment of any out of pocket fees or costs thr ...

Group 1 - CS Disco (LAW) is currently outperforming its peers in the Computer and Technology sector with a year-to-date return of approximately 27.9%, compared to the sector average of 23.2% [4] - The Zacks Rank for CS Disco is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions, with a 10.6% increase in the consensus estimate for full-year earnings over the past 90 days [3] - CS Disco belongs to the Internet - Software industry, which has 168 stocks and is currently ranked 64 in the Zacks Industry Rank, with an average gain of 1.8% this year, further highlighting its strong performance [5] Group 2 - Flex (FLEX) is another notable stock in the Computer and Technology sector, having returned 51.9% since the beginning of the year, and also holds a Zacks Rank of 2 (Buy) [4][5] - The Electronics - Miscellaneous Products industry, where Flex is categorized, has 38 stocks and is ranked 40, with an industry return of +24.7% this year [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of James Hardie Industries plc during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought James Hardie common stock between May 20, 2025, and August 18, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 23, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that James Hardie Industries misled investors regarding the performance of its North America Fiber Cement segment, falsely claiming strong demand while being aware of distributor destocking [5].

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLXNovember 19, 2025 3:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 19, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates i ...

Core Insights - PAO Group, Inc. has launched the AI Positioning Program, a proprietary system aimed at enhancing attorneys' competitive edge in case preparation and litigation outcomes [1] Company Overview - PAO Group, Inc. is recognized as a leading innovator in legal advertising and technology, focusing on attorney performance enhancement [1] Product Details - The AI Positioning Program is designed to provide a significant boost in case performance, offering attorneys advanced tools for strategy and case preparation [1]

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [2][3]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [6]. - The defendants are accused of making false statements regarding the reliability and functionality of the G6 and G7 devices, leading to increased regulatory scrutiny and potential financial harm [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CarMax, Inc. securities between June 20, 2025, and November 5, 2025, about the January 2, 2026, deadline to become lead plaintiffs in a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought CarMax securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by January 2, 2026, to serve as lead plaintiffs [3][5]. - The lawsuit alleges that CarMax's management made materially false and misleading statements regarding the company's growth prospects, which were overstated due to temporary market conditions [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 30, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4] - Specific claims include that Synopsys' focus on artificial intelligence customers was negatively impacting the economics of its Design IP business and that certain decisions were unlikely to yield intended results [4] - The lawsuit asserts that these undisclosed issues had a material negative impact on financial results, leading to misleading positive statements about the company's prospects [4]